ASSASMENT OF THE KNOWLEDGE AND PERCEPTIONS OF THE MALAYSIAN COMMUNITY PHARMACISTS REGARDING PHARMACOVIGILANCE: FINDINGS FROM AN INTERVENTIONAL STUDY

Elkalmi RM1, Hassali MA1, Izham M2

1Universiti Sains Malaysia, Minden, Penang, Malaysia; 2Universiti Sains Malaysia, Pinang, Palau Pinang, Malaysia

OBJECTIVES: To assess the knowledge and perception of community pharmacists in Malaysia toward reporting of adverse drug reactions (ADRs). METHODS: A cross-sectional study employing pre and post intervention design was undertaken with a sample of 42 community pharmacists to explore their knowledge of and the perception toward the pharmacovigilance and ADRs reporting. Changes in scores before and after the completion training program in knowledge and perception were measured. Statistical analysis: The data were analyzed by using SPSS version 17.0 software package (Chicago, IL, USA). Both descriptive and inferential statistics were used when ever appropriate. Frequencies and percentages were used to describe the respondents’ demographic information and professional characteristics. Wilcoxon Signed ranks test, Paired sample t test and The McNemar signed ranks test, Paired sample t test and The McNemar test were employed in this study. RESULTS: Forty-two community pharmacists (CPs) were enrolled in this study. A comparison of CPs knowledge before and immediately after implementation the education program showed significant differences, the participated community pharmacists’ mean scores in knowledge of pharmacovigilance and adverse drug reactions reporting significantly increased compared to the baseline (Z = −5.458, N = 42, P < 0.001). Following the intervention, only few (3, 7.2%) respondents reported that they do not have any ideas on how to report ADR to the relevant authorities in Malaysia. Upon completion of the education program, a large proportion of the pharmacists (45%) believed that they were confident in their knowledge in detection and performing ADRs reporting (z = −2.866, N = 42, P = 0.004). CONCLUSIONS: The finding of the study indicates the need for designing educational programs for the community pharmacists, in order to improve the level of knowledge toward the pharmacovigilance and ADRs reporting process locally.

The cross-country comparison of health performance between tax-funded and social health insurance system: the channel via precautionary care

Chen Q, Li L1

1Peking University, Beijing, China

OBJECTIVES: Tax-funded system and the social health insurance (SHI) system are two main choices for health-care system reform. This research investigates the differences of health outcome and health expenditure between these two systems. The channels of such differences are also valuable for policymaker. We further explore the channel via public health and preventive care investment that leads to these differences. We are also interested in the impact of fiscal and political decentralization on health systems. METHODS: We merge the data from a variety of sources including WHO, the World Bank, OECD together with database prepared by independent researchers like Polivy IV and Government Performance Indicator. After controlling the variables indicating the social-economic situations, we implement the Pooled-OLS Method and Fix Effect Method for panel data. Then check the model specification by testing the autocorrelation of the residuals. RESULTS: When the share of SHI in public health expenditure increases, the total health expenditure (THE) measured as its share in GDP increase dramatically. However, if there is local responsibility, the negative impact will be mitigated. What’s more, the increase of SHI share also plays down the life expectancy, but with local responsibility the negative impact can get ameliorated. It is also found that the impact of health expenditures management in SHI system managed by the share of expenditure in THE and a series of public health behaviors including the immunization rates and infectious disease incidences, presents a consistent pattern. That is, with the increase of the SHI share, the public health performance is weakened, but with local responsibility, the performance will be improved to some extent. CONCLUSIONS: Tax-funded system is more efficient in the sense of cost-benefit, and public health and preventive care investment are important channels of these different performances between the two types of health-care system.

NEW DRUGS AND THE GROWTH OF HEALTH EXPENDITURE: EVIDENCE FROM DIABETIC PATIENTS IN TAIWAN

Lin TM2, Hsiao CR1

1National Cheng Kung University, Taiwan, Taiwan; 2Academia Sinica, Taipei, Taiwan

OBJECTIVES: The aim of this paper is to investigate whether the adoption of pharmaceutical innovation increases the overall expenditure on health care by focusing on diabetic patients. METHODS: By examining the National Health Insurance sampling longitudinal claims data between 2000 and 2004, we use a new class of drugs, namely, thiazolidinediones (TZDs), as an example to investigate the effect on health expenditure of prescribing new drugs to patients by decomposing the impact into treatment substitution and treatment expansion effects. RESULTS: Our results indicate that the introduction of new drugs mainly impacts the outpatient drug expenditure and does not give rise to any offsetting effect on other outpatient and inpatient health expenditures. This suggests that the adoption of pharmaceutical innovation in treating diabetic patients is expenditure-increasing. In addition, we find evidence that the treatment substitution channel has a more significant impact on health expenditure than the treatment expansion channel. CONCLUSIONS: An important policy implication for our finding is that new prescription drugs are better prescribed for themselves, suggesting that the justification for increasing health expenditure on the treatment of diabetes is not conditional upon a lowering in the demand for other types of health-care services. By contrast, it is conditional upon the increased health benefits per se.

ANALYSIS OF AN AFFORDABLE PRICE FOR PERFORMANCE-BASED RISK SHARING SCHEME: OMAZILUMAB ADAPTATION IN KOREA


1Kyung Hee University, Seoul, South Korea; 2University of British Columbia, Vancouver, Canada

OBJECTIVES: The innovative but expensive biologic agents are introduced in recent years, Korea government is meeting with difficulty in funding for these agents due to limited health-care budget. Pay for performance as risk sharing scheme has been adopted to overcome this situation in other countries. In this article we tried to find an affordable price based upon a budget neutral concept and adapted to risk sharing of Omalizumab. METHODS: Omalizumab, for treatment of moderate to severe allergic asthma, is only treated for responders at 16 weeks. We modeled the performance-based risk sharing along four assumptions: 1) no additional national health-care budget, budget of no risk sharing; 2) positive manufacturer’s profit; 3) reimbursed only for responders at 16 weeks; and 4) manufacturer funding to responder in screening period. We also simulated the model by fixing the share of responder in screening period. We also simulated the model by fixing the share of responder in screening period. RESULTS: We defined and analyzed the function of risk sharing scheme based on national health-care budget and manufacturer’s profit. Lower bound of affordable price was derived from the minimum of acceptable predicted sales volume for manufacturer and upper was calculated by a point of budget neutral. Lower bound was highly depends on unit selling price, production cost